pdf   xlsx method abbreviations

mGC or mGEJC - 2nd Line (L2), Ipilimumab (10 mg/kg) , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.54 [0.73, 3.26]< 10%1 study (1/-)12.8 %NAnot evaluable crucial-
progression or deaths (PFS) 1.59 [1.20, 2.10]< 10%1 study (1/-)0.1 %NAnot evaluable important-
irORR 0.24 [0.03, 2.19]> 10%1 study (1/-)10.3 %NAnot evaluable non important-
irPFS 1.44 [1.09, 1.91]< 10%1 study (1/-)0.5 %NAnot evaluable non important-

safety endpoints 00

TRAE (any grade) 2.05 [0.90, 4.67]< 10%1 study (1/-)4.4 %NAnot evaluable non important-
TRAE (grade 3-4) 3.03 [0.91, 10.04]< 10%1 study (1/-)3.5 %NAnot evaluable non important-
TRAE leading to death (grade 5) 1.92 [0.55, 6.70]< 10%1 study (1/-)15.3 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 1.00 [0.02, 51.28]< 10%1 study (1/-)50.0 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Asthenia TRAE (grade 3-4) 1.59 [0.05, 48.47]< 10%1 study (1/-)39.7 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 4.94 [0.24, 101.33]< 10%1 study (1/-)15.3 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 1.59 [0.05, 48.47]< 10%1 study (1/-)39.7 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 8.56 [0.45, 161.00]< 10%1 study (1/-)7.8 %NAnot evaluable non important-
Endocrine disorders TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 3.24 [0.14, 73.60]< 10%1 study (1/-)23.3 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 3.24 [0.14, 73.60]< 10%1 study (1/-)23.3 %NAnot evaluable non important-
Myalgia TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) 0.19 [0.01, 4.33]< 10%1 study (1/-)84.8 %NAnot evaluable non important-
Peripheral neuropathy TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 0.79 [0.02, 40.48]< 10%1 study (1/-)54.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons